ANTICANCER ACTIVITY OF NOVEL COPPER(II) COMPLEX WITH A SCHIFF-BASE LIGAND ON IN VITRO AND IN VIVO OSTEOSARCOMA CANCER MODELS

LUCIA M. BALSA; SOLERNÓ LM; MARIA R. RODRIGUEZ; BEATRIZ PARAJÓN-COSTA; ANA M. GONZALEZ-BARÓ; SOBOL NT; ALONSO DF; GARONA J; IGNACIO E. LEÓN

Mar del Plata

Congreso; Reunión de Sociedades de Biociencia 2021; 2021

Sociedad Argentina de Investigación Clínica

Osteosarcoma (OS) is the most common bone malignant tumor,affecting mainly children and young adults. Cisplatin has beeneffective for the treatment of different solid tumors, including OS.However, cisplatin treatment often results in the development ofchemoresistance and several side effects, leading to therapeuticfailure. In this sense, copper compounds have shown to be poten-tially effective as antitumor agents, attracting increasing interest asalternatives to usually employed platinum derived drugs.The aim of this work is to evaluate the in vitro and in vivo antitumor-al activity against MG-63 cells of the nitrate salt of a novel Cu(II)cationic complex containing a tridentate hydrazone ligand, Cu(HL)for short.Cytotoxic activity on MG-63 cell line was evaluated in 2D (mono-layer) and 3D (spheroids) models. Cu(HL) significantly reduced cellviability after 24 h treatment in both models (IC50 2D: 1.98 ± 0.51μM; 3D: 9.05 ± 1.0 μM) (p